156 results on '"Na, Im Il"'
Search Results
2. Supplementary Data from The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
3. Data from The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
4. A Phase II Study of 131 I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma.
5. Radioimmunotherapy with 131I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma
6. A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma
7. Sex-specific incidence of EGFR mutation and its association with age and obesity in lung adenocarcinomas: a retrospective analysis
8. EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
9. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP
10. A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site
11. Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer
12. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: A single-institution retrospective analysis
13. Decision Tree Model for Predicting Hospice Palliative Care Use in Terminal Cancer Patients
14. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line
15. Family caregiversʼ awareness of illness and attitude toward disclosure during chemotherapy for advanced cancer
16. Evaluation of Adrenal Masses in Lung Cancer Patients Using F-18 FDG PET/CT
17. Clinical significance of 18F-FDG uptake by N2 lymph nodes in patients with resected stage IIIA N2 non-small-cell lung cancer: A retrospective study
18. The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients
19. Clinical significance of 18F-FDG uptake by primary sites in patients with diffuse large B cell lymphoma in the head and neck: a pilot study
20. Association of EGFR mutations in second primary lung cancer and HER2 expression in breast cancer survivors
21. Secondary hematological malignancies in patients with sarcoma: A single‑center retrospective study.
22. Primary gastric lymphoma of T-cell origin: Clinicopathologic features and treatment outcome
23. Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer
24. Multicenter Phase 2 Study of Belotecan, a New Camptothecin Analog, and Cisplatin for Chemotherapy-Naive Patients With Extensive-Disease Small Cell Lung Cancer
25. Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia
26. Phase II Trial of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Gastric Cancer
27. Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
28. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
29. CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib
30. Durable Response to Pazopanib in a Patient with Metastatic Alveolar Soft Part Sarcoma
31. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP
32. A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site
33. Epidermal Growth Factor Receptor Mutations with Metastases in Non-small Cell Lung Cancer
34. Prevalent factor XII deficiency in cancer patients with isolated aPTT prolongation
35. Serum 25-hydroxyvitamin D levels correlation with EGFR mutational status in pulmonary adenocarcinoma.
36. Medullary Thyroid Carcinoma with Ectopic Adrenocorticotropic Hormone Syndrome
37. BRCA1 Gene Mutation in Thymic Malignant Melanoma
38. Epidermal growth factor receptor mutations and brain metastasis in patients with nonadenocarcinoma of the lung.
39. The Effect of Acquired Cisplatin Resistance on Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Cells
40. Association of Epidermal Growth Factor Receptor Mutations with Metastatic Presentations in Non-Small Cell Lung Cancer
41. Evaluation of Adrenal Masses in Lung Cancer Patients Using F-18 FDG PET/CT
42. Prostatic Cancer Presenting as an Isolated Large Lung Mass
43. Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy‐naive patients with extensive‐disease small cell lung cancer
44. The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
45. The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients
46. Four Cases of Hematologic Malignancy Following Radioactive Iodine Therapy for Thyroid Cancer
47. A diagnostic model to detect silent brain metastases in patients with non-small cell lung cancer
48. 18F-Fluoro-2-Deoxy-Glucose Uptake Predicts Clinical Outcome in Patients with Gefitinib-Treated Non–Small Cell Lung Cancer
49. A Case of Epstein-Barr Virus-positive Diffuse, Large B-cell Lymphoma after Angioimmunoblastic T-cell Lymphoma
50. Primary Gastric Choriocarcinoma: Two Case Reports and Review of the Literatures
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.